TD Cowen raised its price target and gave a buy rating for Travere Therapeutics, Inc., while various institutional investors bought into the company.
3 reports, 2 independent
Updated Sep 11
Gone quiet
- Reports
- 3
- Developments
- 3
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
TD Cowen raised its price target and gave a buy rating for Travere Therapeutics, Inc., while various institutional investors bought into the company.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Company filed disclosure with the SEC.1 source
TD Cowen raised its price target and gave a buy rating for Travere Therapeutics, Inc., alongside institutional buying.1 source
TD Cowen adjusted its rating for Travere Therapeutics, Inc., and the company filed disclosures with the SEC.1 source
Keep exploring
Part of
Financial institutions made various moves on June 18, 2026, including TD Cowen lowering its price objective, Citigroup raising its target, and Royal Bank of Canada increasing its target price. Separately, Man Group reduced its stock holdings.Also in this story
- TD Cowen, Citigroup, and Royal Bank of Canada all raised their price targets and objectives for Veeva Systems.
- Analyst reports were issued on Bureau Veritas following rating upgrades by Royal Bank of Canada and Citigroup on June 18, 2026.
- TD Cowen raised its price target for AMD on June 18, 2026.
- Royal Bank of Canada lifted its target price for CarMax on June 18, 2026.
The entities involved
-
TD Cowen
American investment bank
Related events
- TD Cowen raised its price target and issued a buy rating for Globe Life.
- MarketBeat reported that TD Cowen increased its price objective and gave a buy rating for an unnamed company.
- Truist Financial set a $90.00 price target on Edwards Lifesciences shares, and TD Cowen reaffirmed its buy rating and raised the price objective.
- Bio-Techne shares traded on Nasdaq, and TD Cowen reiterated a Buy rating with a $65 price target.
- TD Cowen provided analyst ratings and price targets for Werner Enterprises, while Citigroup also lifted its price target based on company performance.